Health1 min read

STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in China

By · Via STAT Health · Published by Everything Blog

In short

The House Select Committee on China revealed that five leading pharmaceutical manufacturers have pledged to avoid establishing new clinical trials at facilities tied to the Chinese military. The shift follows an inquiry initiated last June examining Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb. Lawmakers opened the probe due to concerns spanning intellectual property risks, ethical practices, and military entanglements in sensitive regions. All five investigated corporations agreed to stop opening studies at these military-connected Chinese sites.

Key points

  • Lawmakers investigated pharmaceutical firms over concerns regarding national security, in…: Lawmakers investigated pharmaceutical firms over concerns regarding national security, intellectual property vulnerabilities, and research ethics.
  • All five targeted pharmaceutical companies agreed to cease launching clinical trials at m…: All five targeted pharmaceutical companies agreed to cease launching clinical trials at medical centers affiliated with the Chinese military.
  • Future clinical research operations by these major drug manufacturers will bypass sensiti…: Future clinical research operations by these major drug manufacturers will bypass sensitive Chinese regions and military-run facilities.

Sources checked by our analysis pipeline: 1

A few of the largest pharmaceutical companies have told a Congressional committee that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military.

The disclosure was made by the House Select Committee on China, which last June opened investigations into five companies — Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb — over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country.

All five companies indicated they would not initiate new clinical studies at sites linked to the People’s Liberation Army, which is the military wing of the Chinese Communist Party. In letters sent to the drugmakers, the House committee noted rising concern over the possibility of security risks.

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Health